Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-04-02 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
上海东洲资产评估有限公司关于《量子高科（中国）生物股份有限公司发行股份购买资产行政许可项目审查一次反馈意见通知书》之反馈意见回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from an asset appraisal company regarding the administrative licensing project review for a share purchase transaction by Quantum Hi-Tech (China) Biological Co., Ltd. It extensively discusses accounting standards compliance, asset valuation, goodwill recognition, and financial forecasts related to a non-controlling interest acquisition. The text references specific accounting standards (Enterprise Accounting Standards No. 20), audit reports, and financial data for fiscal years including 2017 and projections through 2022. The content is technical, focused on financial evaluation, asset appraisal, and compliance with accounting principles, which aligns with an Audit Report or Information document rather than a full Annual Report or Earnings Release. It is not a brief announcement or a presentation but a comprehensive audit-related report on the transaction and valuation. Therefore, the document fits best under the category 'Audit Report / Information' (AR).
2018-04-02 Chinese
普华永道就180154号反馈意见通知书所做回复的专项意见
Audit Report / Information Classification · 95% confidence The document is a detailed audit-related report issued by PwC (普华永道) concerning the financial statements and related matters of a company and its subsidiaries for the years 2015, 2016, and 2017. It includes audit opinions, explanations about related party transactions, pricing fairness, and tax implications of equity transfers. The document references the Chinese Securities Regulatory Commission (中国证监会) feedback and provides detailed responses to regulatory inquiries. The content is focused on audit findings, accounting treatments, and compliance with accounting standards, rather than being a full annual report or earnings release. It is not a brief announcement or a presentation but a comprehensive audit report with professional opinions. Therefore, the document fits the category of an Audit Report / Information (AR).
2018-04-02 Chinese
广发证券股份有限公司关于公司发行股份及支付现金购买资产暨关联交易一次反馈意见的回复之核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed reply to the China Securities Regulatory Commission (CSRC) regarding feedback on a transaction involving the issuance of shares and cash payment for asset acquisition and related party transactions by Quantum Hi-Tech (China) Biological Co., Ltd. It includes extensive financial data, explanations of the transaction structure, funding sources, and legal and financial due diligence opinions. The content is consistent with a formal regulatory response to a regulatory body concerning a major corporate transaction, including detailed financial and legal disclosures. This type of document is typical of a Regulatory Filings (RNS) category, as it is a regulatory submission and response rather than a standalone audit report, annual report, or earnings release. It is not a full annual or interim report, nor a call transcript or presentation. It is also not a simple announcement but a detailed regulatory reply document. Therefore, the best classification is Regulatory Filings (RNS).
2018-04-02 Chinese
广发证券股份有限公司关于公司发行股份及支付现金购买资产暨关联交易项目变更签字注册会计师的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Guangfa Securities Co., Ltd. regarding the change of signing certified public accountants for a major asset restructuring project involving Quantum Hi-Tech (China) Biological Co., Ltd. It details the change of auditors and confirms the validity and accuracy of previously issued audit and review reports. The document does not contain full financial statements or detailed financial analysis but focuses on audit-related confirmations and compliance with regulatory requirements. It is not the audit report itself but a statement about changes in auditors and their opinions on prior audit reports. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and related audit information excluding full annual reports. The document length is 2071 characters, which is short but contains substantive audit-related content rather than just an announcement or certification letter. Hence, it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2018-04-02 Chinese
发行股份及支付现金购买资产暨关联交易报告书
Capital/Financing Update Classification · 95% confidence The document is titled "发行股份及支付现金购买资产暨关联交易报告书," which translates to "Report on Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions." It contains detailed sections on the transaction parties, asset valuation, issuance of shares, lock-up periods, performance commitments, and the impact on the company. It also includes extensive financial data, legal opinions, and risk disclosures related to a major asset acquisition and restructuring. The document is comprehensive and focused on a significant capital transaction involving issuance of shares and cash payment for asset acquisition, which is a capital/financing update rather than a general annual or interim report. It is not a simple announcement or a proxy statement but a detailed transaction report. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification.
2018-04-02 Chinese
关于发行股份及支付现金购买资产暨关联交易报告书的修订说明公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding revisions and supplementary disclosures to a previously issued report titled '发行股份及支付现金购买资产暨关联交易报告书' (Report on Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions). It references regulatory feedback from the China Securities Regulatory Commission and outlines numerous specific updates to the original report, including financial, operational, and risk disclosures. The document is not the original report itself but an announcement explaining the amendments and additional disclosures made to that report. The length is over 5,000 characters, indicating it is substantive, but the content focuses on describing changes to a report rather than presenting full financial statements or comprehensive financial analysis. This fits the category of a Capital/Financing Update (CAP) because it relates to issuance of shares, payment for asset acquisition, and related party transactions, which are financing activities. It is not a full Annual Report or Interim Report, nor is it a simple announcement of report publication. Therefore, the best classification is CAP with high confidence.
2018-04-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.